scholarly journals Cost Effectiveness Analysis of Boceprevir (BOC) Added to Pegifn/Ribavirin (P/R) Versus Pegifn/Ribavirin (Current Standard of Care) for the Treatment of Patients with Genotype 1 Chronic Hepatitis C in Greece

2013 ◽  
Vol 16 (7) ◽  
pp. A352 ◽  
Author(s):  
K. Athanasakis ◽  
E. Karampli ◽  
M.P. Retsa ◽  
T. Theodoropoulou ◽  
J. Kyriopoulos
Sign in / Sign up

Export Citation Format

Share Document